Oragenics
OGENOragenics Inc. is a development-stage biopharmaceutical company focused on the research and commercialization of nasal delivery pharmaceutical therapies for neurological conditions and infectious diseases.
Table of contents
Earnings
Next report
Aug 11, 2026 (In 3 weeks)Competitors
By market cap
By revenue growth
Profile
Oragenics Inc. is a development-stage biopharmaceutical company focused on the research and commercialization of nasal delivery pharmaceutical therapies for neurological conditions and infectious diseases. Its core value proposition centers on a proprietary powder formulation and a breath-propelled intranasal device designed to bypass the blood-brain barrier for rapid drug delivery to the brain. The company's primary focus is advancing its lead neurosteroid candidate for the treatment of mild traumatic brain injury.
A development-stage player focused on a niche intranasal delivery mechanism for mTBI, where there are currently no FDA-approved pharmacological therapies.
Questions, answered.
- What is Oragenics's market cap?
- Oragenics (OGEN) has a market capitalization of $2.5M and trades on AMEX.
- Who are Oragenics's competitors?
- Oragenics's key competitors include Merck & Co., Inc., Pfizer Inc., Johnson & Johnson, and others. These companies compete in similar markets and product categories.
- Who does Oragenics partner with?
- Oragenics's notable partners include Avance Clinical Pty Ltd, Nucleus Network Pty Ltd, Charles River Laboratories International, Inc..
- Where is Oragenics headquartered?
- Oragenics is headquartered in United States of America and employs approximately 5 people. It has been publicly traded since 2003.